tnf-α

TNF-α (31-45), human, is a peptide of tumor necrosis factor-α.

TNF-α (31-45), human (TFA), is a peptide of tumor necrosis factor-α (TNF alpha), an inflammatory cytokine that induces necrosis or apoptosis.

TNF-α (10-36), human, is a potent pro-inflammatory cytokine involved in the acute phase stress response.

Human TNF alpha (46-65) peptide.

TNF-α (31-45), human acetate is a peptide of tumor necrosis factor-α.

TNF-α antagonist is an exocyclic peptide that mimics the critical TNF-α recognition loop on TNF receptor I complex and, thus, prevents ligand interaction with the receptor. By blocking the TNF receptor ligand contact site, this peptide interferes with both activating receptor activator of NF-κB (RANK) and TNF-α's recruitment and activation of osteoclasts. TNF-α antagonist has been used to block bone resorption in the study of systemic bone loss in rheumatoid arthritis and inflammatory bone destruction.

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

TNF-α (31-45), human (TFA) is a peptide of tumor necrosis factor-α.

TNF-α (46-65), human (TFA) is a peptide of human TNF-α.

LEESGGGLVQPGGSMK acetate is a proteolysis peptide found in Infliximab, a chimeric monoclonal IgG1 antibody. It serves as a component of Infliximab and can be employed for the quantitative analysis of this antibody. Infliximab is specifically designed to bind to TNF-α[1].

LEESGGGLVQPGGSMK, a proteolysis peptide, is a component of Infliximab, a chimeric monoclonal IgG1 antibody that selectively binds to TNF-α. It is used for the quantitative assessment of Infliximab.

LEESGGGLVQPGGSMK TFA, a proteolysis peptide component of Infliximab, serves for the quantitative analysis of the latter. Infliximab is a chimeric monoclonal IgG1 antibody, binding specifically to TNF-α [1].

DSTYSLSSTLTLSK TFA, a generic human peptide, facilitates the quantitative detection of Infliximab (Avakine), a chimeric monoclonal IgG1 antibody targeting TNF-α, as indicated in study [1].

Delmitide acetate (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory properties, suppressing TNF-α, IFN-γ, and interleukin (IL)-12 production, while enhancing heme oxygenase 1 activity. It is utilized in research related to ulcerative colitis [1] [2].

ADAM-17 (TACE) and MMP inhibitor; attenuates TNF-α processing. Acts in concert with GM6001 to inhibit Chlamydia trachomatis growth.

Beauvericin, a Fusarium mycotoxin, inhibits acyl-CoA:cholesterol acyltransferase (ACAT) in rat liver microsomal enzyme assays with an IC50 value of 3 μM.

Delmitide, a TNF-alpha production inhibitor, is used potentially for the treatment of Crohn's disease and ulcerative colitis.

N-Formyl-Met-Leu-Phe (N-Formyl-MLF) (fMLF) is a synthetic peptide that acts as an agonist at formyl peptide receptors (FPR; Ki = 0.8 pM).

Epobis, a dendrimeric peptide and recombinant form of erythropoietin, acts as a potent erythropoietin receptor agonist. It fosters neuritogenesis in primary motoneurons, reduces TNF release, and effectively crosses the blood-brain barrier. Additionally, Epobis exhibits anti-inflammatory properties and enhances memory [1].

Anti-Mouse 4-1BB Antibody is a rat-derived IgG2a isotype inhibitor targeting the mouse 4-1BB (CD137) protein.

Macrophage-activating lipopeptide 2 TFA (MALP-2 TFA) is a diacylglycerol lipopeptide and TLR-2/TLR-6 agonist that activates immune cell responses such as macrophages, upregulating TNF, IL-6, and PGE2 to induce local inflammation.

PTD (Antennapedia leader peptide) serves as the negative control for the TRAF6 inhibitory peptide DRQIKIWFQNRRMKWKK-RKIPTEDEY.

RANK-derived TRAF6 inhibitor is a TRAF6 inhibitory peptide that blocks the interaction between TRAF6 and LMP1, with an IC50 of 177 nM. Furthermore, it significantly decreases the viability of LMP1-dependent lymphoblastoid cell lines (LCL).

Hexa-D-arginine is an inhibitor of furin,blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo.